This self-paced online course is designed to provide healthcare professionals, including BCBAs, with foundational knowledge on the use of stimulants and antidepressants in pediatric populations. Topics include psychiatric disorders, mechanisms of action for common medications, treatment considerations, and key safety issues. The course incorporates engaging activities to enhance understanding and practical application of the material.
Pediatric Use of Stimulants and Antidepressants | Learning BCBA CEU Credits: 2
$24.00 Original price was: $24.00.$16.00Current price is: $16.00.
Learning Objectives
- Identify common pediatric psychiatric disorders.
- Differentiate between stimulant and antidepressant medications.
- Understand the mechanisms of action and safety considerations for these medications.
- Analyze case studies to apply knowledge in practical scenarios.
Speaker/Author
Dr. Polina Kalmanovich is a Vice President, Head of Global Program Management at Sarepta Pharmaceuticals. Prior to joining Sarepta, Polina served as the Head of Regulatory and Quality of Novus Therapeutics (an Ear Nose and Throat focused biotechnology company). Prior to joining Novus, Polina worked as a Regulatory Lead in Chase Pharmaceuticals, an Alzheimer’s focused company. She worked at Allergan for over 15 years in total and has been effective in leading global development and registrations in several therapeutic indications, including neurology, infectious disease, pain, urology, and psychiatry. She possesses strong collaborative interpersonal skills, is ethical, trustworthy, reliable and self-motivated. She has outstanding organizational, negotiation and communication skills (verbal and written). She is seen as a highly effective and passionate communicator. She has successfully demonstrated the ability to develop and execute regulatory strategy to achieve key project objectives.
Dr. Kalmanovich holds a Bachelor of Science Degree from the University of California Irvine, a Doctor of Pharmacy Degree and a Master’s of Regulatory Science from the University of Southern California. Most recently, she completed a specialization in leadership and management program from the Harvard Business School and is a graduate of the Harvard Business School’s General Management Program GMP 31.